TORONTO GENERAL HOSPITAL/ST. MICHAEL'S HOSPITAL DEPARTMENTS OF PHARMACY SERVICESHIV SPECIALTY RESIDENCY PROGRAM
EVIDENCE-BASED PHARMACOTHERAPY PRESENTATIONS Objective:
To present a patient and discuss their disease state (s) and drug management in a manner that is clear, concise and interesting.
Format:
1. This is a presentation of an interesting or controversial pharmacotherapy issue within a specialty area. The topic should be a specific question that relates to drug therapy. It should
not be a general overview of an entire disease state. 2. Principles of evidence-based medicine are used to support current management strategies or standards of practice regarding this therapeutic
issue. 3. One to two key articles or studies (e.g., "landmark studies") that relate to the issue should be selected for in-depth discussion. 4. Discuss how the findings from the literature answer the
therapeutic problem, and how the data can be applied to clinical practice. 5. Also critique and discuss limitations of the literature, and identify areas where there are still unanswered questions.
Parameters:
Revised June 1999 Sample Case Scenario/Pre-Reading for Evidence-Based Pharmacotherapy Presentation: Scenario:
You are a clinical pharmacist in an ambulatory area. Your first patient is a 65 year old white male with multiple medical problems referred to you by Internal Medicine Clinic for management of
fluid overload. RJ has a longstanding history of New York Heart Association Class III congestive heart failure (ejection fraction of 30%), coronary artery disease (myocardial infarction 1995, 4
vessel CABG 1995), dyslipidemia and hypertension. The patient was prescribed furosemide 80 m po qam and 80 mg po qpm. Since the new regimen, he states he is feeling much better, has lost 10 lbs,
and can now wear his regular shoes. He states that he can now sleep in his bed with 2 pillows only.
On physical exam:
B/P: 130/64 Heart: S1, S2 + S3, no murmurs HR: 96 regular Lungs: Clear Lower extremity edema: 1+ pitting edema
How would you manage this patient? Would you recommend a beta-blocker?
Reference:
CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
Comments for Evidence-Based Pharmacotherapy Presentations*
*Adapted from: Foisy M. Comments for Critters. Pharm.D. Program Advanced Therapeutics, 1995. |